The Quest to Cure Metastatic Non-Small Cell Lung Cancer With Immunotherapy.
The introduction of immune checkpoint inhibitors targeting the programmed death-1 (PD-1) axis represented a major therapeutic advance, enabling long-term survival, and even cure, in a subset of patients, an outcome previously considered unattainable in metastatic disease. However, most patients do not yet derive sustai...